INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION
Much attention has been placed recently in transplantation in highly HLA-sensitized patients. In attempts to remove these antibodies and enable successful renal transplantation, several approaches have been developed. Intravenous immunoglobulin (IVIG) was found to be effective in the treatment of au...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov
2011-06-01
|
| Series: | Вестник трансплантологии и искусственных органов |
| Subjects: | |
| Online Access: | https://journal.transpl.ru/vtio/article/view/383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849691125924757504 |
|---|---|
| author | A. I. Sushkov Y. G. Moysyuk |
| author_facet | A. I. Sushkov Y. G. Moysyuk |
| author_sort | A. I. Sushkov |
| collection | DOAJ |
| description | Much attention has been placed recently in transplantation in highly HLA-sensitized patients. In attempts to remove these antibodies and enable successful renal transplantation, several approaches have been developed. Intravenous immunoglobulin (IVIG) was found to be effective in the treatment of autoimmune and inflammatory disorders (e. g. Kawasaki disease, Guillain-Barre syndrome). Recently, a beneficial effect of IVIG on the reduc- tion of anti-HLA antibodies was described. The anti-inflammatory effect of IVIG provides hopeful opportunities in antibody-mediated rejection (AMR) management. There are several protocols of IVIG administration for pre-transplant desensitization and AMR treatment: high-dose IVIG, low-dose IVIG + plasmapheresis, IVIG + plasmapheresis + rituximab. These advancements have enabled transplantation in patients previously considered untransplantable and in concert with new diagnostic techniques has resulted in new approaches to management of AMR. |
| format | Article |
| id | doaj-art-44eedc3b05574250aeecdb1ba975bae9 |
| institution | DOAJ |
| issn | 1995-1191 |
| language | Russian |
| publishDate | 2011-06-01 |
| publisher | Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov |
| record_format | Article |
| series | Вестник трансплантологии и искусственных органов |
| spelling | doaj-art-44eedc3b05574250aeecdb1ba975bae92025-08-20T03:21:07ZrusFederal Research Center of Transplantology and Artificial Organs named after V.I.ShumakovВестник трансплантологии и искусственных органов1995-11912011-06-0113211012110.15825/1995-1191-2011-2-110-121326INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTIONA. I. Sushkov0Y. G. Moysyuk1Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, MoscowAcademician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, MoscowMuch attention has been placed recently in transplantation in highly HLA-sensitized patients. In attempts to remove these antibodies and enable successful renal transplantation, several approaches have been developed. Intravenous immunoglobulin (IVIG) was found to be effective in the treatment of autoimmune and inflammatory disorders (e. g. Kawasaki disease, Guillain-Barre syndrome). Recently, a beneficial effect of IVIG on the reduc- tion of anti-HLA antibodies was described. The anti-inflammatory effect of IVIG provides hopeful opportunities in antibody-mediated rejection (AMR) management. There are several protocols of IVIG administration for pre-transplant desensitization and AMR treatment: high-dose IVIG, low-dose IVIG + plasmapheresis, IVIG + plasmapheresis + rituximab. These advancements have enabled transplantation in patients previously considered untransplantable and in concert with new diagnostic techniques has resulted in new approaches to management of AMR.https://journal.transpl.ru/vtio/article/view/383kidney transplantationintravenous immunoglobulinanti-hla antibodiesdesensitizationantibody-mediated rejection. |
| spellingShingle | A. I. Sushkov Y. G. Moysyuk INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION Вестник трансплантологии и искусственных органов kidney transplantation intravenous immunoglobulin anti-hla antibodies desensitization antibody-mediated rejection. |
| title | INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION |
| title_full | INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION |
| title_fullStr | INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION |
| title_full_unstemmed | INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION |
| title_short | INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION |
| title_sort | intravenous immunoglobulin administration for desensitization before renal transplantation and managing antibody mediated rejection |
| topic | kidney transplantation intravenous immunoglobulin anti-hla antibodies desensitization antibody-mediated rejection. |
| url | https://journal.transpl.ru/vtio/article/view/383 |
| work_keys_str_mv | AT aisushkov intravenousimmunoglobulinadministrationfordesensitizationbeforerenaltransplantationandmanagingantibodymediatedrejection AT ygmoysyuk intravenousimmunoglobulinadministrationfordesensitizationbeforerenaltransplantationandmanagingantibodymediatedrejection |